Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Ascendis Pharma A/S (ASND) shares rallied 10.4% in the last trading session to close at $168.84. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.2% gain over the past four weeks.Last month, the company announced robust financial results for the fourth quarter and full year of 2024. This might have driven the recent share price rally.This company is expected to post quarterly loss of $1.55 per share in its upcoming report, which represents a year-over-year change of +37.5%. Revenues are expected to be $96.33 million, down 6.6% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Ascendis Pharma, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on ASND going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Ascendis Pharma belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Repligen (RGEN), closed the last trading session 1.5% higher at $152.81. Over the past month, RGEN has returned 2.5%.For Repligen, the consensus EPS estimate for the upcoming report has changed -6.6% over the past month to $0.35. This represents a change of +25% from what the company reported a year ago. Repligen currently has a Zacks Rank of #3 (Hold).5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ascendis Pharma A/S (ASND): Free Stock Analysis Report Repligen Corporation (RGEN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks